Catechol-O-methyltransferase Val158Met polymorphism on the relationship between white matter hyperintensity and

Mu-En Liu1, Chu-Chung Huang2, Albert C Yang3

  • 1Department of Psychiatry, Taipei Veterans General Hospital, Kaohsiung, Taiwan ; Institute of Brain Science, National Yang-Ming University, Taipei, Taiwan.

Plos One
|February 20, 2014
PubMed
Abstract

Insights

The catechol-O-methyltransferase (COMT) Val158Met gene may influence white matter hyperintensities (WMH) volume and its impact on cognition in healthy adults. Met carriers showed larger WMH volumes, suggesting a genetic link.

Area of Science:

  • Neuroimaging and Genetics
  • Cognitive Neuroscience

Background:

  • White matter hyperintensities (WMH) are visible on MRI and may correlate with cognitive impairment.
  • The relationship between regional WMH and the COMT Val158Met polymorphism in healthy adults is not well understood.

Purpose of the Study:

  • To investigate the genetic effect of COMT Val158Met on regional WMH volumes.
  • To examine how COMT genotype and WMH interact to affect cognitive function in healthy adults.

Main Methods:

  • Recruited 315 ethnic Chinese adults (mean age 54.9 years).
  • Conducted cognitive tests, structural MRI scans, and COMT genotyping.
  • Analyzed regional WMH volumes and cognitive performance in relation to COMT genotype.

Main Results:

  • A negative correlation was found between Digit Span Forward scores and frontal WMH volumes.
  • COMT genotype groups differed in WMH volumes in subcortical, whole brain, and frontal regions.
  • Met homozygotes and heterozygotes had larger WMH volumes than Val homozygotes; this correlation was specific to Met homozygotes.

Conclusions:

  • COMT genotype may modulate WMH volumes in healthy adults.
  • The COMT Val158Met polymorphism might influence the impact of WMH on cognitive function.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
2.0K
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K